RecruitingPhase 2NCT07795814

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction

Sponsor

Edgewise Therapeutics, Inc.

Enrollment

90 participants

Start Date

Aug 25, 2026

Study Type

INTERVENTIONAL

Conditions

Heart Failure With Preserved Ejection Fraction

Summary

This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).

Eligibility

Min Age: 30 YearsMax Age: 84 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called EDG-15400 25 mg, a drug called EDG-15400 50 mg, and others for people with heart failure with preserved ejection fraction. The study is currently recruiting participants at 25 locations. People eligible for this study include aged 30 Years to 84 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEDG-15400 25 mg

EDG-15400 administered orally, once daily

DRUGPlacebo to match EDG-15400 25 mg or 50 mg

Placebo administered orally, once daily

DRUGEDG-15400 50 mg

EDG-15400 administered orally, once daily

Locations(25)

Local Institution - 156

Birmingham, Alabama, United States

Local Institution - 162

Beverly Hills, California, United States

Local Institution - 120

San Diego, California, United States

Local Institution - 149

Vista, California, United States

Local Institution - 153

Peoria, Illinois, United States

Local Institution - 166

Indianapolis, Indiana, United States

Local Institution - 160

Cynthiana, Kentucky, United States

Local Institution - 155

Houma, Louisiana, United States

Local Institution - 106

Baltimore, Maryland, United States

Local Institution - 158

Ypsilanti, Michigan, United States

Local Institution - 164

Jackson, Mississippi, United States

Local Institution - 145

Kansas City, Missouri, United States

Local Institution - 109

St Louis, Missouri, United States

Local Institution - 154

New York, New York, United States

Local Institution - 159

Greensboro, North Carolina, United States

Local Institution - 129

Cincinnati, Ohio, United States

Local Institution - 165

Mechanicsburg, Pennsylvania, United States

Local Institution - 124

Pittsburgh, Pennsylvania, United States

Local Institution - 142

Charleston, South Carolina, United States

Local Institution - 167

Dallas, Texas, United States

Local Institution - 151

Houston, Texas, United States

Local Institution - 157

Houston, Texas, United States

Local Institution - 163

Houston, Texas, United States

Local Institution - 143

Charlottesville, Virginia, United States

Local Institution - 132

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07795814

Related Trials

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459628 locations

Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization Versus Medical Rate Control

NCT0683313815 locations

Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition

NCT064095851 location

Incretin Therapies in Obesity-related HFpEF

NCT07554638

A Preliminary Study for INFORMED

NCT05585125